Catalyst Pharmaceutical Inc. (CPRX) Dividend History

Company News

• Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day

  Santhera Pharmaceuticals will provide an update on the commercial progress of its drug AGAMREE for the treatment of Duchenne Muscular Dystrophy, as well as outline its strategic plans for further market expansion and diversification of its rare disease portfolio.

  GlobeNewswire Inc.
• Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?

  Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  Zacks Investment Research

  Featured Companies: ESPR
• A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals

  Catalyst Pharmaceuticals (NASDAQ:CPRX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 3 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $28.43, along with a high estimate of $34.00 and a low estimate of $23.00. Marking an increase of 7.98%, the current average surpasses the previous average price target of $26.33. Analyzing Analyst Ratings: A Detailed Breakdown The perception of Catalyst Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Andrew Fein HC Wainwright & Co. Maintains Buy $26.00 $26.00 Andrew Fein HC Wainwright & Co. Raises Buy $26.00 $24.00 Leland Gershell Oppenheimer Maintains Outperform $29.00 $29.00 Charles Duncan Cantor Fitzgerald Maintains Overweight $34.00 - Charles Duncan Cantor Fitzgerald Maintains Overweight $34.00 - Samantha Semenkow Citigroup Announces Buy $27.00 - Jason Gerberry B of A Securities Announces Buy $23.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' ...Full story available on Benzinga.com

  Benzinga
• Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®

  CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE® (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”). The increased maximum daily dose offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS.

  GlobeNewswire Inc.
• Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024

  CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Jefferies Global Healthcare Conference 2024 on Wednesday, June 5, 2024, in New York.

  GlobeNewswire Inc.